Cargando…
Project ECHO Revisited: Propensity Score Analysis And HCV Treatment Outcomes
Propensity score analysis is a statistical approach to reduce bias often present in non-randomized observational studies. In this paper we use this method to re-analyze data from a study that assessed whether patients receiving HCV treatment from providers in Project ECHO had different clinical outc...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789170/ https://www.ncbi.nlm.nih.gov/pubmed/31632162 http://dx.doi.org/10.2147/HMER.S212855 |
_version_ | 1783458594478358528 |
---|---|
author | Page, Kimberly Qeadan, Fares Qualls, Clifford Thornton, Karla Arora, Sanjeev |
author_facet | Page, Kimberly Qeadan, Fares Qualls, Clifford Thornton, Karla Arora, Sanjeev |
author_sort | Page, Kimberly |
collection | PubMed |
description | Propensity score analysis is a statistical approach to reduce bias often present in non-randomized observational studies. In this paper we use this method to re-analyze data from a study that assessed whether patients receiving HCV treatment from providers in Project ECHO had different clinical outcomes than patients treated by specialists from an academic medical center (UNM HCV clinic) but in which treatment assignment was not randomized. We modeled the best estimated probability of treatment assignment, and then assess differences overall SVR and SVR in patients with genotype 1 infection by treatment arm using Stabilized Inverse Probability of Treatment Weights (SIPTW). Results show that after adjustment for SIPTW, HCV treatment outcomes were significantly better for the ECHO patients compared to the UNM HCV clinic patients. Higher proportions of patients treated by primary care providers achieved SVR and SVR with genotype 1 compared to those treated at UNM HCV clinic with 15.1% and 16.3% absolute differences, respectively. These results indicate that previously published results (showing no differences) were biased, and resulted in an underestimation of the treatment effect of ECHO on HCV treatment. |
format | Online Article Text |
id | pubmed-6789170 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-67891702019-10-18 Project ECHO Revisited: Propensity Score Analysis And HCV Treatment Outcomes Page, Kimberly Qeadan, Fares Qualls, Clifford Thornton, Karla Arora, Sanjeev Hepat Med Short Report Propensity score analysis is a statistical approach to reduce bias often present in non-randomized observational studies. In this paper we use this method to re-analyze data from a study that assessed whether patients receiving HCV treatment from providers in Project ECHO had different clinical outcomes than patients treated by specialists from an academic medical center (UNM HCV clinic) but in which treatment assignment was not randomized. We modeled the best estimated probability of treatment assignment, and then assess differences overall SVR and SVR in patients with genotype 1 infection by treatment arm using Stabilized Inverse Probability of Treatment Weights (SIPTW). Results show that after adjustment for SIPTW, HCV treatment outcomes were significantly better for the ECHO patients compared to the UNM HCV clinic patients. Higher proportions of patients treated by primary care providers achieved SVR and SVR with genotype 1 compared to those treated at UNM HCV clinic with 15.1% and 16.3% absolute differences, respectively. These results indicate that previously published results (showing no differences) were biased, and resulted in an underestimation of the treatment effect of ECHO on HCV treatment. Dove 2019-10-07 /pmc/articles/PMC6789170/ /pubmed/31632162 http://dx.doi.org/10.2147/HMER.S212855 Text en © 2019 Page et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Short Report Page, Kimberly Qeadan, Fares Qualls, Clifford Thornton, Karla Arora, Sanjeev Project ECHO Revisited: Propensity Score Analysis And HCV Treatment Outcomes |
title | Project ECHO Revisited: Propensity Score Analysis And HCV Treatment Outcomes |
title_full | Project ECHO Revisited: Propensity Score Analysis And HCV Treatment Outcomes |
title_fullStr | Project ECHO Revisited: Propensity Score Analysis And HCV Treatment Outcomes |
title_full_unstemmed | Project ECHO Revisited: Propensity Score Analysis And HCV Treatment Outcomes |
title_short | Project ECHO Revisited: Propensity Score Analysis And HCV Treatment Outcomes |
title_sort | project echo revisited: propensity score analysis and hcv treatment outcomes |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789170/ https://www.ncbi.nlm.nih.gov/pubmed/31632162 http://dx.doi.org/10.2147/HMER.S212855 |
work_keys_str_mv | AT pagekimberly projectechorevisitedpropensityscoreanalysisandhcvtreatmentoutcomes AT qeadanfares projectechorevisitedpropensityscoreanalysisandhcvtreatmentoutcomes AT quallsclifford projectechorevisitedpropensityscoreanalysisandhcvtreatmentoutcomes AT thorntonkarla projectechorevisitedpropensityscoreanalysisandhcvtreatmentoutcomes AT arorasanjeev projectechorevisitedpropensityscoreanalysisandhcvtreatmentoutcomes |